- The share
- Press releases
- Financial calendar
- Financial reports
- Prospectus and material offerings
- Financial presentations
- Corporate governance
- Analyst Coverage
- CODE OF CONDUCT
- Thank you
Nomination committee of XVIVO Perfusion AB (publ)
The following members have been appointed to XVIVO Perfusion’s nomination committee for the 2021 annual general meeting:
Henrik Blomquist, appointed by Bure Equity AB
Caroline Sjösten, appointed by Swedbank Robur Fonder AB
Martin Lewin, appointed by Eccenovo AB
Gösta Johannesson, chairman of the board of directors
The appointments have been made in accordance with the instructions regarding principles for the appointment of the company’s nomination committee which were established by the annual general meeting of XVIVO Perfusion AB (publ) on April 27, 2018. The shareholders that have appointed the members of the nomination committee represented in aggregate 30 percent of all shares in the company as of 31 August 2020.
The nomination committee shall prepare and submit proposals to the annual general meeting 2021 regarding (i) election of chairman of the meeting, (ii) resolution on number of board members, (iii) election of and resolution on remuneration to the chairman of the board and the board members, (iv) election of and resolution on remuneration to the auditor, and (v) resolution on new procedure for appointing the nomination committee if the nomination committee deems it to be necessary.
The annual general meeting of XVIVO Perfusion AB (publ) will be held on April 22, 2021 in Gothenburg. Shareholders who wish to submit proposals to the nomination committee are welcome to do so in due time before the annual general meeting 2021 so that the nomination committee has time to consider the proposal. Proposals may be sent to XVIVO Perfusion AB (publ), Att: Nomination committee, P.O. Box 53015, SE‑400 14 Gothenburg, Sweden.
September 30, 2020
XVIVO Perfusion AB (publ)
For further information please contact:
XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in the USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com.